Carfilzomib and Paclitaxel Co-Loaded Protein Nanoparticles an Effective Therapy Against Pancreatic Adenocarcinomas

References

• American Society of Clinical Oncology. Pancreatic cancer: types of treatment. Internet. Cancer.Net Editorial Board; June 8, 2021. Available from: https://www.cancer.net/cancer-types/pancreatic-cancer/types-treatment. Accessed September 28, 2021.
   Google Scholar
• Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15(1):8–18. doi:10.1016/j.pan.2014.10.001
   PubMed Web of Science ®Google Scholar
• Lei F, Xi X, Batra SK, Bronich TK. Combination therapies and drug delivery platforms in combating pancreatic cancer. J Pharmacol Exp Ther. 2019;370(3):682–694. doi:10.1124/jpet.118.255786
   PubMed Web of Science ®Google Scholar
• Wang JP, Wu CY, Yeh YC, et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015;6(20):18162–18173. doi:10.18632/oncotarget.4216
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Fraunhoffer NA, Abuelafia AM, Bigonnet M, et al. Evidencing a pancreatic Ductal Adenocarcinoma subpopulation sensitive to the proteasome inhibitor Carfilzomib. Clin Cancer Res. 2020;26(20):5506–5519. doi:10.1158/1078-0432.Ccr-20-1232
   PubMedGoogle Scholar
• Kawaguchi K, Igarashi K, Murakami T, et al. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer Patient-Derived Orthotopic Xenograft (PDOX). Oncotarget. 2017;8(29):47490. doi:10.18632/oncotarget.17667
   PubMedGoogle Scholar
• Roeten MSF, Cloos J, Jansen G. Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother Pharmacol. 2018;81(2):227–243. doi:10.1007/s00280-017-3489-0
   PubMed Web of Science ®Google Scholar
• Naumann K, Schmich K, Jaeger C, Kratz F, Merfort I. Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines. Anticancer Drugs. 2012;23(6):614–626. doi:10.1097/CAD.0b013e3283504e53
   PubMedGoogle Scholar
• Papadopoulos KP, Burris HA 3rd, Gordon M, et al. A Phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;72(4):861–868. doi:10.1007/s00280-013-2267-x
   PubMedGoogle Scholar
• Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014;12(1):94. doi:10.1186/s12915-014-0094-0
   PubMedGoogle Scholar
• Park JE, Chun SE, Reichel D, et al. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: anticancer efficacy and pharmacokinetic studies in mice. PLoS One. 2017;12(3):e0173247. doi:10.1371/journal.pone.0173247
   PubMedGoogle Scholar
• Park JE, Park J, Jun Y, et al. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. J Control Release. 2019;302:148–159. doi:10.1016/j.jconrel.2019.04.006
   PubMed Web of Science ®Google Scholar
• Peng Q, Zhang S, Yang Q, et al. Preformed albumin Corona, a protective coating for nanoparticles based drug delivery system. Biomaterials. 2013;34(33):8521–8530. doi:10.1016/j.biomaterials.2013.07.102
   PubMed Web of Science ®Google Scholar
• Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013;1830(12):5526–5534. doi:10.1016/j.bbagen.2013.04.023
   PubMed Web of Science ®Google Scholar
• Park J, Park JE, Hedrick VE, et al. A comparative in vivo study of albumin-coated Paclitaxel Nanocrystals and Abraxane. Small. 2018;14(16):e1703670. doi:10.1002/smll.201703670
   PubMedGoogle Scholar
• Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself–implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26(2):77–100. doi:10.1016/s1040-8428(97)00015-2
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317–1324. doi:10.1158/1078-0432.Ccr-05-1634
   PubMed Web of Science ®Google Scholar
• Guarneri V, Dieci MV, Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother. 2012;13(3):395–406. doi:10.1517/14656566.2012.651127
   PubMed Web of Science ®Google Scholar
• Kudarha RR, Sawant KK. Albumin based versatile multifunctional nanocarriers for cancer therapy: fabrication, surface modification, multimodal therapeutics and imaging approaches. Mater Sci Eng C Mater Biol Appl. 2017;81:607–626. doi:10.1016/j.msec.2017.08.004
   PubMed Web of Science ®Google Scholar
• Sage H, Johnson C, Bornstein P. Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem. 1984;259(6):3993–4007. doi:10.1016/S0021-9258(17)43194-2
   PubMed Web of Science ®Google Scholar
• Hoogenboezem EN, Duvall CL. Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev. 2018;130:73–89. doi:10.1016/j.addr.2018.07.011
   PubMed Web of Science ®Google Scholar
• Han H, Wang J, Chen T, Yin L, Jin Q, Ji J. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment. J Colloid Interface Sci. 2017;507:217–224. doi:10.1016/j.jcis.2017.07.047
   PubMed Web of Science ®Google Scholar
• Yu Q, Qiu Y, Li J, et al. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy. J Control Release. 2020;321:564–575. doi:10.1016/j.jconrel.2020.02.040
   PubMed Web of Science ®Google Scholar
• Yin T, Dong L, Cui B, et al. A toxic organic solvent-free technology for the preparation of PEGylated paclitaxel nanosuspension based on human serum albumin for effective cancer therapy. Int J Nanomedicine. 2015;10:7397–7412. doi:10.2147/ijn.S92697
   PubMed Web of Science ®Google Scholar
• Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011;39(10):1873–1882. doi:10.1124/dmd.111.039164
   PubMed Web of Science ®Google Scholar
• Chen RF. Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem. 1967;242(2):173–181. doi:10.1016/S0021-9258(19)81445-X
   PubMedGoogle Scholar
• Cheng WJ, Chen LC, Ho HO, Lin HL, Sheu MT. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy. Int J Nanomedicine. 2018;13:7079–7094. doi:10.2147/ijn.S181440
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.Can-09-1947
   PubMed Web of Science ®Google Scholar
• Chang CE, Hsieh CM, Chen LC, et al. Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer. Drug Deliv. 2018;25(1):632–643. doi:10.1080/10717544.2018.1440444
   PubMed Web of Science ®Google Scholar
• Cheng WJ, Lin SY, Chen M, et al. Active tumoral/tumor environmental dual-targeting by non-covalently arming with trispecific antibodies or dual-bispecific antibodies on docetaxel-loaded mPEGylated nanocarriers to enhance chemotherapeutic efficacy and Minimize systemic toxicity. Int J Nanomedicine. 2021;16:4017–4030. doi:10.2147/ijn.S301237
   PubMedGoogle Scholar
• Min JS, Kim J, Kim JH, et al. Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal. 2017;146:341–346. doi:10.1016/j.jpba.2017.08.048
   PubMedGoogle Scholar
• Kuo ZK, Lin MW, Lu IH, et al. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. BMC Complement Altern Med. 2016;16(1):277. doi:10.1186/s12906-016-1250-6
   PubMedGoogle Scholar
• Vlasova I, Saletsky A. Study of the denaturation of human serum albumin by sodium dodecyl sulfate using the intrinsic fluorescence of albumin. J Appl Spectrosc. 2009;76(4):536–541. doi:10.1007/s10812-009-9227-6
   Web of Science ®Google Scholar
• Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11(11):4136–4143. doi:10.1158/1078-0432.Ccr-04-2291
   PubMed Web of Science ®Google Scholar
• Ernsting MJ, Murakami M, Undzys E, Aman A, Press B, Li S-D. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J Control Release. 2012;162(3):575–581. doi:10.1016/j.jconrel.2012.07.043
   PubMed Web of Science ®Google Scholar
• He X, Xiang N, Zhang J, et al. Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity. Int J Pharm. 2015;487(1–2):250–259. doi:10.1016/j.ijpharm.2015.04.047
   PubMed Web of Science ®Google Scholar
• Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121(6):893–897. doi:10.1182/blood-2012-10-459883
   PubMed Web of Science ®Google Scholar